Akintunde Bello

Akintunde Bello

Bristol-Myers Squibb Co. - New York / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4390351
-
person_outline Akintunde Bello's MOST POPULAR ARTICLES
1-) Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer Annals of Oncology 29 (11), 2208-2213, 2018
2-) Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug Pharmaceutical research 29, 427-440, 2012
3-) Clinical pharmacology considerations for the development of immune checkpoint inhibitors The Journal of Clinical Pharmacology 57, S26-S42, 2017
4-) Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drugM Morgen, C Bloom, R Beyerinck, A Bello, W Song, K Wilkinson, ...Pharmaceutical research 29, 427-440, 20121642012
5-) Clinical pharmacology considerations for the development of immune checkpoint inhibitorsJ Sheng, S Srivastava, K Sanghavi, Z Lu, BJ Schmidt, A Bello, M GuptaThe Journal of Clinical Pharmacology 57, S26-S42, 20171302017